TOUR study of Vibativ reports use in S. aureus infections in real world setting.- Theravance Biopharma.

Theravance Biopharma announced that positive new data from multiple studies of Vibativ (telavancin) in treating infection from the ongoing Telavancin Observational Use Registry (TOUR) study, which is designed to report how telavancin is being used by healthcare practitioners to treat patients in real-world clinical settings. Researchers presented data reported for 159 patients captured in the TOUR study who were diagnosed with monomicrobial S. aureus infections with vancomycin MIC of at least 1 �g/mL . Of these Vibativ was used as a second-line or greater therapy in 77.4% of patients, with 44.0% having previously been treated with vancomycin. Among the 144 patients who had an outcome assessment at end of therapy with Vibativ, a positive clinical response was reported for 77.1%, with 9.7% failing to respond to treatment and 13.2% having an indeterminate clinical outcome. The patients' most common infection types were complicated skin and skin structure infections (45.9%), bacteremia and endocarditis (20.1%), and osteomyelitis (15.7%).

Researchers also presented data reported for 308 patients captured in the TOUR study who received Vibativ therapy for longer than 21 days. Of these patients, 76.3% were treated with Vibativ as second-line or greater therapy, with 65.6% of patients treated as outpatients prior to starting Vibativ therapy. This prolonged treatment led to no change in renal function for 68.7% of these sick patients. Data were presented at IDWeek 2018.